Vaxart, Inc.
US ˙ OTCPK ˙ US92243A2006

Introduction

This page provides a comprehensive analysis of the known insider trading history of Dunne Michael W.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Dunne Michael W. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ITRM / Iterum Therapeutics plc Director 235,001
US:VXRT / Vaxart, Inc. Director 75,000
US:DRTX / Durata Therapeutics Inc Chief Medical Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Dunne Michael W.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases VXRT / Vaxart, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in VXRT / Vaxart, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VXRT / Vaxart, Inc. Insider Trades
Insider Sales VXRT / Vaxart, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in VXRT / Vaxart, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VXRT / Vaxart, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Dunne Michael W. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-12 2025-08-08 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 15,000 235,001 6.82 0.72 10,854 170,047
2024-08-12 2024-08-06 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 106,247 220,001 93.40
2023-12-27 2023-12-22 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 25,000 113,754 28.17 1.40 35,000 159,256
2023-12-19 2023-12-18 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 10,000 88,754 12.70 1.84 18,442 163,680
2023-11-27 2023-11-22 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 20,000 78,754 34.04 2.03 40,690 160,225
2023-10-02 2023-10-01 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 3,487 58,754 6.31
2023-07-03 2023-07-01 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 1,779 55,267 3.33
2023-06-15 2023-06-15 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 15,853 53,488 42.12
2023-06-05 2023-04-01 4/A ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 1,299 37,635 3.57
2023-04-03 2023-04-01 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 1,299 37,636 3.57
2023-01-04 2023-01-01 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 761 36,337 2.14
2022-09-09 2022-09-07 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 10,000 35,576 39.10 2.22 22,200 78,979
2022-06-24 2022-06-23 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 36,798 383,647 10.61
2022-03-29 2022-03-25 4 ITRM Iterum Therapeutics plc
Restricted Share Units
A - Award 11,426 11,426
2022-03-29 2022-03-25 4 ITRM Iterum Therapeutics plc
Restricted Share Units
M - Exercise -10,494 0 -100.00
2022-03-29 2022-03-25 4 ITRM Iterum Therapeutics plc
Ordinary Shares
M - Exercise 10,494 346,849 3.12
2021-07-27 2021-07-25 4 ITRM Iterum Therapeutics plc
Ordinary Shares
A - Award 80,000 336,355 31.21
2021-06-25 2021-06-23 4 ITRM Iterum Therapeutics plc
Restricted Stock Units
A - Award 36,798 36,798
2021-03-29 2021-03-25 4 ITRM Iterum Therapeutics plc
Restricted Stock Units
A - Award 10,494 10,494
2021-01-27 2021-01-26 4 ITRM Iterum Therapeutics plc
Ordinary Shares
S - Sale -33,143 256,355 -11.45 1.73 -57,337 443,494
2021-01-27 2021-01-25 4 ITRM Iterum Therapeutics plc
Ordinary Shares
A - Award 80,000 289,498 38.19
2020-10-28 2020-10-27 4 ITRM Iterum Therapeutics plc
Warrants (right to buy)
P - Purchase 46,155 46,155
2020-10-28 2020-10-27 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 61,540 209,498 41.59
2019-02-19 2019-02-15 4 ITRM Iterum Therapeutics plc
Stock Option (Right to Buy)
A - Award 85,000 85,000
2018-09-06 2018-09-04 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 500 147,958 0.34 10.00 5,000 1,479,580
2018-08-28 2018-08-27 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 500 147,458 0.34 10.00 5,000 1,474,580
2018-08-28 2018-08-24 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 500 146,958 0.34 10.00 5,000 1,469,580
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Series B-2 Preferred Shares
C - Conversion -2,917 0 -100.00
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Series B-1 Preferred Shares
C - Conversion -4,050 0 -100.00
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Series A Preferred Shares
C - Conversion -12,730 0 -100.00
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Ordinary Shares
P - Purchase 2,000 146,458 1.38 13.00 26,000 1,903,954
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Ordinary Shares
C - Conversion 2,917 144,458 2.06
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Ordinary Shares
C - Conversion 4,050 141,541 2.95
2018-05-30 2018-05-30 4 ITRM Iterum Therapeutics plc
Ordinary Shares
C - Conversion 12,730 137,491 10.20
2018-05-29 2018-05-24 4 ITRM Iterum Therapeutics plc
Stock Option (Right to Buy)
A - Award 79,567 79,567
2018-05-24 3 ITRM Iterum Therapeutics plc
Ordinary Shares
249,522
2018-05-24 3 ITRM Iterum Therapeutics plc
Ordinary Shares
249,522
2018-05-24 3 ITRM Iterum Therapeutics plc
Ordinary Shares
249,522
2017-05-22 2017-05-18 4 AVIR Aviragen Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 20,000 75,000 36.36 0.49 9,800 36,750
2016-05-13 2016-05-12 4 AVIR Aviragen Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 20,000 20,000 1.50 30,000 30,000
2015-10-21 2015-09-21 4 BOTA Biota Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 35,000 35,000 1.95 68,250 68,250
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -100,000 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -50,000 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -12,500 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -18,850 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
D - Sale to Issuer -281,250 0 -100.00
2014-11-18 2014-11-17 4 DRTX Durata Therapeutics, Inc.
Common Stock
D - Sale to Issuer -13,220 0 -100.00
2014-05-22 2014-05-21 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
A - Award 100,000 462,600 27.58
2013-02-14 2013-02-12 4 DRTX Durata Therapeutics, Inc.
Stock Option (right to buy)
A - Award 50,000 362,600 15.99 7.49 374,500 2,715,874
2012-07-26 2012-07-24 4 DRTX Durata Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -89,764 0 -100.00
2012-07-26 2012-07-24 4 DRTX Durata Therapeutics, Inc.
Common Stock
C - Conversion 11,220 11,220
2012-07-26 2012-03-15 4 DRTX Durata Therapeutics, Inc.
Series A Convertible Preferred Stock
P - Purchase 25,581 89,764 39.86 1.00 25,581 89,764
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)